xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06018376</url>
    </required_header>
    <id_info>
      <org_study_id>GECP 23/01_LUDICAS</org_study_id>
      <nct_id>NCT06018376</nct_id>
    </id_info>
    <brief_title>Characteristics of Sexual Dysfunction in Patients With Lung Cancer</brief_title>
    <acronym>LUDICAS</acronym>
    <official_title>Characteristics of Sexual Dysfunction in Patients With Lung Cancer</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Fundación GECP</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Fundación GECP</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The general objective of this observational study is identify and describe the type,&#xD;
        frequency, and severity of sexual dysfunction in patients with lung cancer and generate&#xD;
        strategies for clinical management and oncological follow-up directed and based on the&#xD;
        specific findings in this population. The recruitment will be carried out from July 2023 and&#xD;
        will be carried out until December 2023, the analysis of the information will be carried out&#xD;
        from January to March 2024.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        It is planned to develop a study with a larger number of patients with lung cancer, including&#xD;
        the population of Spain and Latin American countries to obtain a sample of more diverse and&#xD;
        heterogeneous characteristics, with clinical, cultural, and sociodemographic differences.&#xD;
        This will make it possible to obtain better and greater data and therefore define the&#xD;
        clinical and treatment factors significantly associated with DS in these individuals and&#xD;
        obtain a more complete vision of the reality of the problem.&#xD;
  &#xD;
        The results of this research will make it possible to carry out interventions specifically&#xD;
        directed at this population and to modify the oncological follow-up guidelines currently in&#xD;
        force. Likewise, the information collected will serve as the basis for generating new&#xD;
        protocols for a multidisciplinary approach, including the participation of psychology and&#xD;
        specialists in urology, gynecology, and psychiatry.&#xD;
  &#xD;
        The general objective of this observational study is identify and describe the type,&#xD;
        frequency, and severity of sexual dysfunction in patients with lung cancer and generate&#xD;
        strategies for clinical management and oncological follow-up directed and based on the&#xD;
        specific findings in this population. The recruitment will be carried out from July 2023 and&#xD;
        will be carried out until December 2023, the analysis of the information will be carried out&#xD;
        from January to March 2024.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">July 13, 2023</start_date>
    <completion_date type="Anticipated">March 30, 2024</completion_date>
    <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Case-Only</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Number of Participants with different type, frequency and severity of sexual dysfunction</measure>
      <time_frame>From inclusion up to 3 months</time_frame>
      <description>Identify and describe the type, frequency, and severity of DS in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Number of participants with risk factors for the development and severity of sexual dysfunction.</measure>
      <time_frame>From inclusion up to 3 months</time_frame>
      <description>Analysis of risk factors for the development and severity of sexual dysfunction described in the clinical history and study questionnaires.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with sexual dysfunction according to different characteristics</measure>
      <time_frame>From inclusion up to 3 months</time_frame>
      <description>To characterize the differences in sexual dysfunction in patients with lung cancer according to age, sociodemographic characteristics, region of residence, and type of cancer treatment.</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Anticipated">500</enrollment>
    <condition>Lung Cancer</condition>
    <condition>Sexual Dysfunction</condition>
    <arm_group>
      <arm_group_label>Observational Study Group</arm_group_label>
      <description>Age greater than or equal to 18 years and less than or equal to 70 years.&#xD;
  Diagnosis of lung cancer stages IB to IV.&#xD;
  Having received systemic oncological treatment for at least 3 months&#xD;
  ECOG ≤ 2</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Systemic oncological treatment</intervention_name>
      <description>Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months</description>
      <arm_group_label>Observational Study Group</arm_group_label>
      <other_name>chemotherapy</other_name>
      <other_name>radiotherapy</other_name>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Patients with lung cancer stages IB to IV with ECOG ≤ 2 between 18 and 70 years old that&#xD;
          received systemic oncological treatment for at least 3 months.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age greater than or equal to 18 years and less than or equal to 70 years.&#xD;
  &#xD;
            -  Diagnosis of lung cancer stages IB to IV.&#xD;
  &#xD;
            -  Having received systemic oncological treatment for at least 3 months or being in&#xD;
               oncological follow-up after having received systemic treatment for a minimum of 3&#xD;
               months with stable tumor disease or partial or complete response in images.&#xD;
  &#xD;
            -  ECOG ≤ 2&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients with comorbidities (renal failure, cardiovascular diseases or similar) not&#xD;
               controlled with corresponding medical management.&#xD;
  &#xD;
            -  Individuals with physical disability or cognitive impairment that prevents them from&#xD;
               completing the electronic data collection form.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
    </eligibility>
    <overall_official>
      <last_name>Aylen Vanessa Ospina Serrano, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Hospital Puerta del Hierro Investigator</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Eva Pereira</last_name>
      <phone>+34 934302006</phone>
      <email>gecp@gecp.org</email>
    </overall_contact>
    <location>
      <facility>
        <name>Instituto Alexander Flemming</name>
        <address>
          <city>Buenos Aires</city>
          <country>Argentina</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Claudio Martín, MD</last_name>
      </contact>
      <investigator>
        <last_name>Claudio Martín, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Oncomedica, IMAT</name>
        <address>
          <city>Montería</city>
          <state>Monteria</state>
          <country>Colombia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Sandra Arauchan, MD</last_name>
      </contact>
      <investigator>
        <last_name>Sandra Arauchan, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Clínica Universitaria Colombia</name>
        <address>
          <city>Bogotá</city>
          <country>Colombia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Pedro Ramos, MD</last_name>
      </contact>
      <investigator>
        <last_name>Pedro Ramos, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Clinica del Occidente</name>
        <address>
          <city>Cali</city>
          <country>Colombia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Giovanna Rivas, MD</last_name>
      </contact>
      <investigator>
        <last_name>Giovanna Rivas, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hematooncologos SA</name>
        <address>
          <city>Cali</city>
          <country>Colombia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Ana Avendaño, MD</last_name>
      </contact>
      <investigator>
        <last_name>Ana Avendaño, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Clínica de Medellín</name>
        <address>
          <city>Medellín</city>
          <country>Colombia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Nathalia Arango, MD</last_name>
      </contact>
      <investigator>
        <last_name>Nathalia Arango, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>ALIADAS Instituto Nacional de Enfermedades Neoplasicas</name>
        <address>
          <city>Surquillo</city>
          <zip>15038</zip>
          <country>Peru</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Tanya Runciman, MD</last_name>
      </contact>
      <investigator>
        <last_name>Tanya Runciman, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Centro Hospitalar do Porto</name>
        <address>
          <city>Porto</city>
          <zip>4099-001</zip>
          <country>Portugal</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Antonio Araújo, MD</last_name>
      </contact>
      <investigator>
        <last_name>Antonio Araújo, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital General de Elche</name>
        <address>
          <city>Elche</city>
          <state>Alicante</state>
          <zip>03203</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Maria Guirado Risueño, MD</last_name>
      </contact>
      <investigator>
        <last_name>Maria Guirado Risueño, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>ICO Badalona, Hospital Germans Trias i Pujol</name>
        <address>
          <city>Badalona</city>
          <state>Barcelona</state>
          <zip>08916</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Pau Guillén Sentís, MD</last_name>
      </contact>
      <investigator>
        <last_name>Pau Guillén Sentís, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital General de Granollers</name>
        <address>
          <city>Granollers</city>
          <state>Barcelona</state>
          <zip>08402</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Silvia Muñoz, MD</last_name>
      </contact>
      <investigator>
        <last_name>Silvia Muñoz, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital La Mancha Centro</name>
        <address>
          <city>Alcázar De San Juan</city>
          <state>Ciudad Real</state>
          <zip>13600</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Sara Cerezo, MD</last_name>
      </contact>
      <investigator>
        <last_name>Sara Cerezo, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospitalario Universitario A Coruña</name>
        <address>
          <city>A Coruña</city>
          <state>La Coruña</state>
          <zip>15006</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Rosario García Campelo, MD</last_name>
      </contact>
      <investigator>
        <last_name>Rosario García Campelo, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital de Fuenlabrada</name>
        <address>
          <city>Fuenlabrada</city>
          <state>Madrid</state>
          <zip>28942</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>María Sereno Moyano, MD</last_name>
      </contact>
      <investigator>
        <last_name>María Sereno Moyano, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario Puerta de Hierro</name>
        <address>
          <city>Majadahonda</city>
          <state>Madrid</state>
          <zip>28222</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Vanessa Ospina, MD</last_name>
      </contact>
      <investigator>
        <last_name>Vanessa Ospina, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Infanta Sofia</name>
        <address>
          <city>San Sebastián De Los Reyes</city>
          <state>Madrid</state>
          <zip>28702</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>María Sereno Moyano, MD</last_name>
      </contact>
      <investigator>
        <last_name>María Sereno Moyano, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario Cruces</name>
        <address>
          <city>Barakaldo</city>
          <state>Vizcaya</state>
          <zip>48903</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Eider Azkona, MD</last_name>
      </contact>
      <investigator>
        <last_name>Eider Azkona, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitari Vall d' Hebron</name>
        <address>
          <city>Barcelona</city>
          <zip>08035</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Augusto Valdivia, MD</last_name>
      </contact>
      <investigator>
        <last_name>Augusto Valdivia, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital General Universitario de Ciudad Real</name>
        <address>
          <city>Ciudad Real</city>
          <zip>13005</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Patricia Patricia, MD</last_name>
      </contact>
      <investigator>
        <last_name>Patricia Cruz, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario Lucus Augusti</name>
        <address>
          <city>Lugo</city>
          <zip>27003</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Begoña Campos, MD</last_name>
      </contact>
      <investigator>
        <last_name>Begoña Campos, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Clínico San Carlos</name>
        <address>
          <city>Madrid</city>
          <zip>28040</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Mónica Antoñanzas Basa, MD</last_name>
      </contact>
      <investigator>
        <last_name>Mónica Antoñanzas Basa, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario Fundación Jiménez Díaz</name>
        <address>
          <city>Madrid</city>
          <zip>28040</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Manuel Dómine, MD</last_name>
      </contact>
      <investigator>
        <last_name>Manuel Dómine, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitari Son Llatzer</name>
        <address>
          <city>Palma De Mallorca</city>
          <zip>07198</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Juan Coves Sarto, MD</last_name>
      </contact>
      <investigator>
        <last_name>Juan Coves Sarto, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Clínico de Salamanca</name>
        <address>
          <city>Salamanca</city>
          <zip>37007</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Alejandro Olivares Hernández, MD</last_name>
      </contact>
      <investigator>
        <last_name>Alejandro Olivares Hernández, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario Nuestra Señora de Candelaria</name>
        <address>
          <city>Santa Cruz De Tenerife</city>
          <zip>38010</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Ana Cardeña Gutierrez, MD</last_name>
      </contact>
      <investigator>
        <last_name>Ana Cardeña Gutierrez, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Xarxa sanitaria Santa Tecla- Tarragona</name>
        <address>
          <city>Tarragona</city>
          <zip>43003</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Laia Capdevila, MD</last_name>
      </contact>
      <investigator>
        <last_name>Laia Capdevila, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital General Universitario de Valencia</name>
        <address>
          <city>Valencia</city>
          <zip>46014</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Ana Blasco, MD</last_name>
      </contact>
      <investigator>
        <last_name>Ana Blasco, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Universitario La Fe</name>
        <address>
          <city>Valencia</city>
          <zip>46026</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Francisco Aparisi, MD</last_name>
      </contact>
      <investigator>
        <last_name>Francisco Aparisi, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Hospital Clínico Universitario de Valladolid</name>
        <address>
          <city>Valladolid</city>
          <zip>47003</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Rafael López, MD</last_name>
      </contact>
      <investigator>
        <last_name>Rafael López, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>Argentina</country>
      <country>Colombia</country>
      <country>Peru</country>
      <country>Portugal</country>
      <country>Spain</country>
    </location_countries>
    <link>
      <url>http://www.gecp.org</url>
      <description>Web page of the sponsor where users can find more information about Fundación GECP studies</description>
    </link>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 25, 2023</study_first_submitted>
    <study_first_submitted_qc>August 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 30, 2023</study_first_posted>
    <last_update_submitted>August 30, 2023</last_update_submitted>
    <last_update_submitted_qc>August 30, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Lung Cancer</keyword>
    <keyword>Sexual Dysfunction</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lung Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06018376
  org study id: GECP 23/01_LUDICAS
  nct id: NCT06018376
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The general objective of this observational study is identify and describe the type,
        frequency, and severity of sexual dysfunction in patients with lung cancer and generate
        strategies for clinical management and oncological follow-up directed and based on the
        specific findings in this population. The recruitment will be carried out from July 2023 and
        will be carried out until December 2023, the analysis of the information will be carried out
        from January to March 2024.
  It is planned to develop a study with a larger number of patients with lung cancer, including
        the population of Spain and Latin American countries to obtain a sample of more diverse and
        heterogeneous characteristics, with clinical, cultural, and sociodemographic differences.
        This will make it possible to obtain better and greater data and therefore define the
        clinical and treatment factors significantly associated with DS in these individuals and
        obtain a more complete vision of the reality of the problem.
  
        The results of this research will make it possible to carry out interventions specifically
        directed at this population and to modify the oncological follow-up guidelines currently in
        force. Likewise, the information collected will serve as the basis for generating new
        protocols for a multidisciplinary approach, including the participation of psychology and
        specialists in urology, gynecology, and psychiatry.
  
        The general objective of this observational study is identify and describe the type,
        frequency, and severity of sexual dysfunction in patients with lung cancer and generate
        strategies for clinical management and oncological follow-up directed and based on the
        specific findings in this population. The recruitment will be carried out from July 2023 and
        will be carried out until December 2023, the analysis of the information will be carried out
        from January to March 2024.
  observational model: Case-Only
  time perspective: Prospective
  measure: Number of Participants with different type, frequency and severity of sexual dysfunction
  time frame: From inclusion up to 3 months
  description: Identify and describe the type, frequency, and severity of DS in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population.
  measure: Number of participants with risk factors for the development and severity of sexual dysfunction.
  time frame: From inclusion up to 3 months
  description: Analysis of risk factors for the development and severity of sexual dysfunction described in the clinical history and study questionnaires.
  measure: Number of participants with sexual dysfunction according to different characteristics
  time frame: From inclusion up to 3 months
  description: To characterize the differences in sexual dysfunction in patients with lung cancer according to age, sociodemographic characteristics, region of residence, and type of cancer treatment.
  arm group label: Observational Study Group
  description: Age greater than or equal to 18 years and less than or equal to 70 years.
  Diagnosis of lung cancer stages IB to IV.
  Having received systemic oncological treatment for at least 3 months
  ECOG ≤ 2
  intervention type: Drug
  intervention name: Systemic oncological treatment
  description: Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
  arm group label: Observational Study Group
  other name: chemotherapy
  other name: radiotherapy
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 70 Years
  last name: Aylen Vanessa Ospina Serrano, MD
  role: Study Chair
  affiliation: Hospital Puerta del Hierro Investigator
  last name: Eva Pereira
  phone: +34 934302006
  email: gecp@gecp.org
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  country: Argentina
  country: Colombia
  country: Peru
  country: Portugal
  country: Spain
  url: http://www.gecp.org
  description: Web page of the sponsor where users can find more information about Fundación GECP studies
  responsible party type: Sponsor
  mesh term: Lung Neoplasms
  sharing ipd: No